@inproceedings{oai:repo.qst.go.jp:00054427,
 author = {Imai, Reiko and 今井 礼子},
 book = {NIRS＆MedAustron　Joint Symposium on Carbon Ion Radiotherapy},
 month = {Dec},
 note = {Abstract
A clinical trial was first initiated in 1996 to evaluate the safety and efficacy of carbon ion radiotherapy for bone and soft tissue sarcomas not suitable for surgery. As of March 2013, over 900 patients were enrolled in the clinical trials. Through a dose escalation trial and a subsequent fixed dose trial, it was revealed that carbon ion radiotherapy provided definite local control and offered a survival advantage without unacceptable morbidity for patients with bone and soft tissue sarcomas that were either difficult or impossible to cure using other modalities. The most commonly treated sarcoma at NIRS was sacral chordoma, followed by axial high-grade bone and soft-tissue sarcomas. This part deals with carbon ion radiotherapy for unresectable sarcomas below C2.},
 pages = {24--31},
 title = {Carbon Ion Radiotherapy for Bone and Soft Tissue sarcomas.},
 year = {2013}
}